KBC Group: Publication of transparency notification(s) received by KBC Group NV

Press release

Outside trading hours – Regulated information*

Brussels, 18 May 2021, 18h00

Publication of transparency notification(s) received by KBC Group NV

(art. 14, 1st section of the Act of 2 May 2007 concerning the disclosure of significant participations)

Summary of the notification(s)

KBC Group NV has received a transparency notification on 7 May 2021, which states that The Capital Group Companies, Inc.("CGC") has crossed the reporting threshold of 3% (total voting rights and equivalent financial instruments) upwards, to 3.01%.

Content of the notification(s)

The notification(s) contain(s) following information:

• Reason for the notification(s): acquisition or disposal of voting securities or voting rights
• Notification(s) by: CGC
• Persons subject to the notification requirement: see annex
• Date(s) on which the threshold is crossed: 4 May 2021.
• Threshold that is crossed: 3%

(KBC Group’s Articles of Association set a notification threshold of 3% of the total number of voting rights. In addition, the legal thresholds of 5% or any multiple thereof also apply)

• Denominator (number of shares KBC Group NV): 416 694 558
• Notified details: see annex.
• Chain of controlled undertakings through which the holding is effectively held:
  See “11: Full chain of controlled undertakings through which the holding is effectively held” in the PDF-file(s) on www.kbc.com (see below).
• The relevant notification(s) is (are) available at www.kbc.com > Investor relations > Shareholder information > Shareholder structure.

For more information, please contact:

Kurt De Baenst, General Manager, Investor Relations, KBC Group

E-mail: [email protected]

Viviane Huybrecht, General Manager, Corporate Communication/Spokesperson, KBC Group

E-mail: [email protected]

You May Also Be Interested In

• Baker Hughes and Venture Global Advance Next Phase of U.S. Gas Infrastructure Growth
• CB&I AND AG&P INDUSTRIAL ACHIEVE FIRST-OF-ITS-KIND MILESTONE WITH ALL-STEEL FULL CONTAINMENT LNG TANKS IN THE PHILIPPINES
• Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer